The attenuation of EAE severity by the genetic deletion of ATX from CD11b+ cells, also considering the other likely sources of ATX expression in the inflamed CNS, suggest possible therapeutic benefits of targeting ATX in EAE/MS. This evidence concerns the gene ENPP2 and myeloid sarcoma.